Inactivated vaccine-elicited potent antibodies can broadly neutralize SARS-CoV-2 circulating variants

Liu, Yubin; Wang, Ziyi; Zhuang, Xinyu; Zhang, Shengnan; Chen, Zhicheng; Yan, Zaoxue; Sheng, Jie; Li, Tianpeng; Tai, Wanbo; Yu, Jinfang; Wang, Yanqun; Zhang, Zhaoyong; Chen, Yunfeng; Tong, Liangqin; Yu, Xi; Wu, Linjuan; Chen, Dong; Zhang, Renli; Jin, Ningyi; Shen, Weijun; Zhao, Jincun; Tian, Mingyao; Wang, Xinquan; Cheng, Gong

doi:10.1038/s41467-023-37926-7

Cited by 21 publications

(35 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our antibody array primarily consists of memory B-cell derived antibodies that are studied to be broadly neutralizing against different variants (23, 24, 30). Our results support the empirical results that our antibody array, primarily consisting of broadly neutralizing antibodies, maintains their efficacy across different variants (23, 24, 30). The presence of such broadly neutralizing antibodies also may indicate a level of prevalence of memory B-cells within vaccinated individuals that generate such antibodies (23, 30, 50, 51).…”

Section: Discussionmentioning

confidence: 99%

“…Other available SARS-CoV-2 Spike RBD crystal structures were downloaded from the Protein Data Bank (PDB) (21). We derived the WT and BA.1 RBD structures from the Protein Data Bank as they represent empirically derived structures from an RBD-Antibody or RBD-ACE2 complex (22)(23)(24)(25)(26)(27)(28)(29)(30)(31). B.…”

Section: Methodsmentioning

confidence: 99%

“…Note that the BNT162b2-CorV vaccine is commonly known as the "Pfizer-BioNtech" vaccine. BBIBP-CorV was developed by Sinopharm and was the first whole inactivated virus SARS-CoV-2 vaccination to obtain an emergency use authorization by the World Health Organization (23). The entries without a vaccine are antibodies obtained from unvaccinated patients before mass SARS-CoV-2 vaccination was available in the USA.…”

Section: Methodsmentioning

confidence: 99%

“…We downloaded other available SARS-CoV-2 Spike RBD crystal structures from the Protein Data Bank (PDB) (28). We derived the WT and BA.1/B.1.1.529 RBD structures from the Protein Data Bank as they represent empirically derived structures from an RBD-Antibody or RBD-ACE2 complex (29)(30)(31)(32)(33)(34)(35)(36)(37)(38). For every RBD-antibody and RBD-ACE2 complex we isolated on PDB, we extracted the RBD structure from that complex.…”

Section: Viral Proteinsmentioning

confidence: 99%

See 3 more Smart Citations

Predicting Antibody and ACE2 Affinity for SARS-CoV-2 BA.2.86 and JN.1 withIn SilicoProtein Modeling and Docking

Yasa,

Guirales-Medrano,

Machado

et al. 2023

Preprint

View full text Add to dashboard Cite

The emergence of the Omicron sublineage of SARS-CoV-2 virus BA.2.86 (nicknamed “Pirola”) has raised concerns about its potential impact on public health and personal health as it has many mutations with respect to previous variants. We conducted anin silicoanalysis of neutralizing antibody binding to BA.2.86. Selected antibodies came from patients who were vaccinated and/or infected. We predicted binding affinity between BA.2.86 and antibodies. We also predicted the binding affinity between the same antibodies and several previous SARS-CoV2 variants (Wuhan and Omicron descendants BA.1, BA.2, and XBB.1.5). Additionally, we examined binding affinity between BA.2.86 and human angiotensin converting enzyme 2 (ACE2) receptor, a cell surface protein crucial for viral entry. We found no statistically significant difference in binding affinity between BA.2.86 and other variants, indicating a similar immune response. These findings contradict media reports of BA.2.86’s high immune evasion potential based on its mutations. We discuss the implications of our findings and highlight the need for modeling and docking studies to go above and beyond mutation and basic serological neutralization analysis. Future research in this area will benefit from increased structural analyses of memory B-cell derived antibodies and should emphasize the importance of choosing appropriate samples forin silicostudies to assess protection provided by vaccination and infection. This research contributes to understanding the BA.2.86 variant’s potential impact on public health. Moreover, we introduce new methodologies for predictive medicine in ongoing efforts to combat the evolving SARS-CoV-2 pandemic and prepare for other hazards.

show abstract